Global Cell And Gene Therapy Overview
Cell and Gene Therapy Market accounted for US$ 13.0 billion in 2022 and is estimated to be US$ 62.5 billion by 2032 and is anticipated to register a CAGR of 22.8%.
Cell and Gene Therapy Market are overlapping fields of biomedical research with similar therapeutic goals, targeting DNA or RNA inside or outside the body. Both therapies aim to modify the genetic material to treat the disease. Gene therapy uses genetic material or DNA to treat an inherited or acquired disease, while cell therapy involves introducing new cells into a patient's body to grow, replace, or repair damaged tissue to treat the disease. A variety of cell types can be used in cell therapy, including stem cells, lymphocytes, dendritic cells, and pancreatic islet cells. Cell and gene therapy plays an important role in new health care, as it provides concepts and techniques that can be used in gene regulation, reproductive potential, and remodeling. Cell and gene therapies provide significant advances among patient care by treating or possibly curing a different type of diseases that were previously untreatable by small molecule and biological drugs. Cell therapy and gene therapy are fields of biomedical research and treatment, both this therapies aim to treat, prevent, or potentially cure disease, and both methods have the potential to address the root cause of genetic and acquired diseases. Cell and gene therapies provide significant advances in patient care and helping to treat or potentially cure a range of conditions untapped by small molecules and biologic agents. After decades of effort, the future of gene and cell therapy is incredibly promising, with recent breakthroughs recognizing life-changing benefits for patients and many products in development. Cell and gene therapy is growing as steady investment and consolidation in cell and gene therapy contributed to the growth of the cell and gene therapy market. The most common type of gene therapy involves inserting a normal gene to replace an abnormal gene, other methods include: replacing an abnormal gene with a normal gene, gene repair. Cell and gene therapy represent overlapping areas of research with similar therapeutic goals—developing a treatment that can correct the underlying cause of a disease, often a rare inherited condition that can be life-threatening or debilitating and has limited options. The cell and gene therapy market is expected to grow during the forecast period due to the increasing prevalence of cardiovascular disease and the launch of new therapies and collaborations by key market players are the major factors that will drive the market growth during the forecast period. However, the market is primarily driven by the exponential growth in the clinical pipeline and the increase in the number of regulatory approvals for innovative drugs.
Global Cell And Gene Therapy Dynamics
The major factor driving the cell and gene therapy market is an increased pool of patients with various diseases, product launches and approvals. Also, favorable regulatory support and special designations for cell and gene therapy products, growing demand for car t-cell therapy products. Increasing prevalence of cancer and chronic diseases, rising number of clinical trials for cell and gene therapy, steady investment and consolidation in the market and favorable regulatory environment will further boost the target market growth. Cell and gene therapies find their increased use in treating incurable disease conditions, providing safe and efficacious treatment compared to small molecule drugs and monoclonal antibodies. Car t-cell therapy addresses current challenges in cancer care through superior efficacy, safety, and delivery mechanisms. Car t-cell therapy has brought itself into focus due to the personalized nature of this therapy and the utilization of advanced genetic engineering technology. The wide acceptance and use of car t-cell therapy are fueling the growth of the cell and gene therapy market. The market is expected to grow at a significant growth rate due to the opportunities that lie within its domain, which include drug approvals and a strong pipeline of cell and gene therapies. Increasing strategic acquisition activities, increasing funding for cell and gene therapy r&d activities, expanding end-user of cell and gene therapy products will provide lucrative growth opportunity to the market. However, there are significant challenges which are restraining the market growth. These challenges include the high cost of therapy and lack of therapy-specific assays. Manufacturing and operational challenges, availability of alternative treatments and withdrawal of products will hinder the market.
Technological advancement
Advances and innovative technologies in the field of cell and gene therapy usher in a new era for biological therapies. Also the PRIME designation and marketing authorization for products provides manufacturers with a new opportunity for financing and revenue generation. Recombinant DNA (rDNA) technology has made possible the transfer of genes from one organism to another, the use of rDNA technology in combination with humans and other mammals is known as gene therapy, gene therapy can be classified into two categories, germinal and somatic. In February 2022, researchers developed a heteroduplex oligonucleotide technology that silences specific genes whose high expression levels cause disease. Advance therapies use stem cells to kick-start the regeneration process, creating healthy cells and repairing damaged ones Stem cells are the main components of all cells in the body and have the remarkable ability to develop into any cell. Therefore, new technologies were needed to purposefully insert genes into site-specific locations, genome editing is an engineering method that uses nucleases or molecular scissors to deliberately alter the genome of living organisms. A new CRISPR-based tool that inserts large DNA sequences into cells at desired locations, known as PASTE, has the potential to treat a variety of diseases caused by defective genes. Products involved in Cell and Gene Therapy The market is developing advanced versions of their products due to new age technological advancements. Key players in cell and gene therapy are investing more in power systems and creating more modern, time-saving, cost-effective technologies that will positively impact the bio-polyamides market. In September 2022, companies launching new cell and gene therapies can deliver on their promise to transform patients' lives by properly preparing the market, their products, and internal go-to-market models.
Global Cell And Gene Therapy Segmentation
Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.
The cell and gene therapy market is segmented based on products, distribution channel type, end-users, and region.
Cell and Gene therapy market, By Products
Based on products, the cell and gene therapy market is segmented into cell therapy and gene therapy. The cell therapy market is growing at a steady rate, and this trend is expected to continue during the forecast period due to the increased patient base with a wide range of diseases/ailments. Gene therapy is expected to be highest due to the increased patient base for the existing gene remedy products, expected the launch of other gene therapy-based products for several indications, and expanded indication approvals for existing commercially available products.
Cell and Gene therapy market, By Distribution Channel
Based on the distribution channel type, the target market is segmented into oncology, dermatology, musculoskeletal, and others. The oncology segment accounts for the highest share of the market. The growth of the oncology segment is increasing at a fast rate on account of the growing prevalence of several types of cancers. Currently, the available products not only modify the disease but also improve the quality of the patient's life, thereby decreasing the mortality rate. The market in the dermatology segment is increasing at a steady rate. This segment owns its growth to the increasing incidence and prevalence rate of several types of wounds, which are difficult to treat under normal conditions and the launch of innovative products.
Cell and Gene therapy market, By End-Users
Based on end-users, the target market is bifurcated into Hospitals, Wound Care Centers, Cancer Care Centers, Ambulatory Surgical Centers, and Others. The hospital is growing mainly due to the increasing incidence/prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic wound on account of diabetes feet, pressure ulcers, and other injuries.
Regional Insights:
On region the Cell and Gene Therapy Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounts highest revenue share to the cell and gene therapy market due to the high prevalence of chronic diseases and other conditions, which require these treatment methods. Asia Pacific cell and gene therapy market is projected to register a high CAGR over the forecast period owing to the growing prevalence of cancers, osteoarthritis, burns, and other chronic wounds, the introduction of advanced products.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2022 |
|
Forecast period |
2022 – 2032 |
|
Market representation |
Revenue in USD Billion & CAGR from 2022 to 2032 |
|
Market Segmentation |
By Product - Cell Therapy, and Gene Therapy By Distribution Channel – Oncology, Dermatology, Musculoskeletal, and Others By End-User – Hospitals, Wound Care Centers, Cancer Care Centers, Ambulatory Surgical Centers, and Others |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Cell and Gene Therapy Market report based on product, distribution channel, end-user and Region.
Cell and Gene Therapy Market, By Product:
- Cell Therapy
- Gene Therapy
Cell and Gene Therapy Market, By Distribution Channel:
- Oncology
- Dermatology
- Musculoskeletal
- Others
Cell and Gene Therapy Market, By End User:
- Hospitals
- Wound Care Centers
- Cancer Care Centers
- Ambulatory Surgical Centers
- Others
Cell and Gene Therapy Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
-
- U.S.
- Canada
- Middle East & Africa
Global Cell And Gene Therapy Key Players
The key players operating the Cell and Gene Therapy Market includes, Gilead Sciences, Spark Therapeutics, Novartis AG, Organogenesis, Amgen, Osiris Therapeutics, Dendreon, Vericel, Anterogen, Tego Sciences. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market. For instance, in December 2019, Kite, a Gilead Company, and the CIBMTR, the research collaboration between the National Marrow Donor Program®, be the Match and the Medical College of Wisconsin announced findings from an ongoing post-marketing study evaluating the safety and efficacy of Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.
Global Cell And Gene Therapy Key Issues Addressed
Recent Developments:
- In December 2022, Emmens is dedicating the center to furthering the company's legacy and depth in cell and gene therapy research. The company, a , full-service clinical research organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, said in a news release that the center will focus on supporting clinical trials for its customers who are developing cell and gene therapies, Worldwide and in many therapeutic areas, including ophthalmology and rare diseases.
- In October 2022, Gilead will partner with a California biotechnology startup to find new ways to make cancer cell therapy safer and more effective. The deal with Refuse Biotechnologies, announced in October, gives Gilead exclusive rights to use the biotech's synthetic biology technology to develop blood cancer treatments.
- Novartis has entered into an initial agreement with Charisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to develop a HER 2 targeted CAR-M cell therapy to be tested in early trials for the treatment of solid tumors.
Global Cell And Gene Therapy Company Profile
- Gilead Sciences*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Spark Therapeutics
- Novartis AG
- Organogenesis
- Amgen
- Osiris Therapeutics
- Dendreon
- Vericel
- Anterogen
- Tego Sciences.
“*” marked represents similar segmentation in other categories in the respective section
Global Cell And Gene Therapy Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Industry Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Cell and Gene Therapy Strategies
- Key Questions this Study will Answer
- Market Snippet, By-Products
- Market Snippet, By Distribution Channel Type
- Market Snippet, By End-Users
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Products, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Cell Therapy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Gene Therapy
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, Distribution Channel Products, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Oncology
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Dermatology]
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Musculoskeletal
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, By End-Users, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Hospitals
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Wound Care Centers
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Care Centers
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Ambulatory Surgical Centers
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Distribution Channel Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-Users, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Distribution Channel Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-Users, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Distribution Channel Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-Users, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Distribution Channel Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-Users, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Products, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Distribution Channel Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By End-Users, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
-
- Gilead Sciences
- Company Overview
- Product and Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Spark Therapeutics
- Novartis AG
- Organogenesis
- Amgen
- Osiris Therapeutics
- Dendreon
- Vericel
- Anterogen
- Tego Sciences
- Gilead Sciences
-
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
Cell and Gene Therapy Market accounted for US$ 13.0 billion in 2022 and is estimated to be US$ 62.5 billion by 2032 and is anticipated to register a CAGR of 22.8%.
The Cell and Gene Therapy Market is projected to increase at a CAGR of 22.8% during the forecast period.
The global cell and gene therapy market is segmented based on products, distribution channel type, end-users, and region.
The major factor driving the global cell and gene therapy market is an increased pool of patients with various diseases, product launches and approvals.
In 2019, North America accounted for the largest share of the market, followed by Europe. The rising prevalence of chronic diseases, high and growing healthcare expenditure, presence of advanced healthcare infrastructure, availability of reimbursements, and the presence of major market players in the region are the major factors driving the growth of the gene therapy market in North America.
Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market.